scholarly journals Does the Energy Restriction Intermittent Fasting Diet Alleviate Metabolic Syndrome Biomarkers? A Randomized Controlled Trial

Nutrients ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 3213
Author(s):  
Yasemin Ergul Kunduraci ◽  
Hanefi Ozbek
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Weight Loss ◽  
Healthy Eating ◽  
Healthy Eating Index ◽  
Energy Restriction ◽  
Controlled Study ◽  
Intermittent Fasting ◽  
Model Assessment ◽  
Randomized Controlled

The aim of this study was to determine the efficacy of an energy restriction intermittent fasting diet in metabolic biomarkers and weight management among adults with metabolic syndrome. This randomized controlled study was performed with metabolic syndrome patients, aged 18–65 years, at an academic institution in Istanbul, Turkey (n = 70). All participants were randomized to the Intermittent Energy Restriction (IER) intervention group and Continuous Energy Restriction (CER) control group. Biochemical tests including lipid profile, fasting plasma glucose, insulin, glycosylated hemoglobin Type A1c (HbA1c), homeostatic model assessment of insulin resistance (HOMA-IR), blood pressure, and body composition were evaluated at baseline and at the 12th week in diet interviews. Dietary intake was measured with the 24-h dietary recall method and dietary quality was evaluated with the Healthy Eating Index-2010. Changes in body weight (≈7% weight loss) and composition were similar in both groups. Blood pressure, total cholesterol, triglyceride, low-density lipoprotein (LDL), fasting glucose, and insulin at the 12th week decreased in both groups (p < 0.05). No significant differences were observed in metabolic syndrome biomarkers between the IER and CER groups. The energy-restricted intermittent fasting diet did not cause any deficiencies in macronutrient and fiber intake in the subjects. Healthy Eating Index (HEI) index scores were achieved similarly in both groups, and subjects’ dietary intakes were close to daily reference nutritional intake values. The technique used to achieve energy restriction, whether intermittent or continuous, appears to alleviate the metabolic syndrome biomarkers activated by weight loss.

Physiological and Therapeutic Outcomes of Intermittent Fasting versus Calorie-Restriction Diet in Patients suffering from Metabolic Syndrome

2019 ◽  
Vol 3 (1) ◽  
pp. 4-19
Author(s):  
Doreen Susanne Micallef
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Weight Loss ◽  
Blood Glucose ◽  
Calorie Restriction ◽  
Fasting Blood Glucose ◽  
Hdl Cholesterol ◽  
Intermittent Fasting ◽  
Retrospective Case ◽  
Restriction Diet

The main objective of this study was to determine whether an intermittent fasting diet in combination with a CR diet results in better outcomes on risk factors associated with metabolic syndrome (such as lowering of triglycerides, fasting blood glucose, and blood pressure decrease in abdominal obesity and an increase in HDL-cholesterol and related weight loss for both male and female patients) than with a conventional CR diet alone. A 12-week retrospective case-control study was carried out and involved 78 females and 22 males who exhibited or were receiving medications for three or more conditions related to metabolic syndrome and who completed the study out of 120 participants at baseline. These were randomly assigned to either a conventional calorie-restriction diet or to an intermittent-fasting diet. Relevant baseline parameters were measured during the first encounter and were then repeated after twelve weeks. Professional contact was maintained on a fortnightly basis for both groups. Subjects randomly assigned to the intermittent fasting diet lost more weight than subjects on a conventional calorie-restriction diet after 12 weeks (mean ± SD, 5.7 ± 3.2 kg vs 11.4 ± 6.4 kg; p < 0.001). There were also statistically significant decreases in waist circumference (10.1 ± 7.2 cm vs 4.5 ± 3.3 cm; p < 0.001), serum triglycerides (0.31 ± 0.29 mmol/l vs 0.16 ± 0.16 mmol/l; p = 0.002), and systolic blood pressure (11.1 ± 8.2 mm Hg vs 5.2 ± 4.8 mm Hg; p < 0.001) and an increase in HDL-cholesterol (0.25 ± 0.16 vs 0.14 ± 0.15 mmol/l; p = 0.001). However, no statistically significant changes in diastolic blood pressure and fasting blood glucose were recorded. The intermittent fasting diet gave better weight loss outcomes (6.67% vs 12.35%) than did the conventional calorie restriction diet when compared to the baseline weight after the conclusion of the 12-week programme. The intermittent fasting diet was also associated with statistically significant improvements in four out of the six parameters measured and associated with metabolic syndrome. Longer-term studies are required to determine whether these outcomes will be maintained over longer periods of time assuming that there is compliance by the participants.

scholarly journals Effects of Regular Kefir Consumption on Gut Microbiota in Patients with Metabolic Syndrome: A Parallel-Group, Randomized, Controlled Study

Nutrients ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 2089 ◽  
Author(s):  
Ezgi BELLIKCI-KOYU ◽  
Banu Pınar SARER-YUREKLI ◽  
Yakut AKYON ◽  
Fadime AYDIN-KOSE ◽  
Cem KARAGOZLU ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Gut Microbiota ◽  
Relative Abundance ◽  
Controlled Study ◽  
Microbiota Composition ◽  
Randomized Controlled ◽  
Parallel Group ◽  
Significant Difference ◽  
Gut Microbiota Composition

Several health-promoting effects of kefir have been suggested, however, there is limited evidence for its potential effect on gut microbiota in metabolic syndrome This study aimed to investigate the effects of regular kefir consumption on gut microbiota composition, and their relation with the components of metabolic syndrome. In a parallel-group, randomized, controlled clinical trial setting, patients with metabolic syndrome were randomized to receive 180 mL/day kefir (n = 12) or unfermented milk (n = 10) for 12 weeks. Anthropometrical measurements, blood samples, blood pressure measurements, and fecal samples were taken at the beginning and end of the study. Fasting insulin, HOMA-IR, TNF-α, IFN-γ, and systolic and diastolic blood pressure showed a significant decrease by the intervention of kefir (p ≤ 0.05, for each). However, no significant difference was obtained between the kefir and unfermented milk groups (p > 0.05 for each). Gut microbiota analysis showed that regular kefir consumption resulted in a significant increase only in the relative abundance of Actinobacteria (p = 0.023). No significant change in the relative abundance of Bacteroidetes, Proteobacteria or Verrucomicrobia by kefir consumption was obtained. Furthermore, the changes in the relative abundance of sub-phylum bacterial populations did not differ significantly between the groups (p > 0.05, for each). Kefir supplementation had favorable effects on some of the metabolic syndrome parameters, however, further investigation is needed to understand its effect on gut microbiota composition.

scholarly journals Randomized Controlled Trial of Once-Per-Week Intermittent Fasting for Health Improvement: The WONDERFUL Trial

2021 ◽  
Author(s):  
Ciera L Bartholomew ◽  
Joseph B Muhlestein ◽  
Heidi T May ◽  
Viet T Le ◽  
Oxana Galenko ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Disease Onset ◽  
Low Frequency ◽  
Density Lipoprotein ◽  
Health Improvement ◽  
Intermittent Fasting ◽  
Model Assessment ◽  
Randomized Controlled

Abstract Background Low-density lipoprotein cholesterol (LDL-C) predicts heart disease onset and may be reduced by intermittent fasting. Some studies, though, reported that fasting increased LDL-C; however, no study evaluated LDL-C as the primary endpoint. This randomized controlled trial evaluated the effect of low-frequency intermittent fasting on LDL-C and other biomarkers. Methods Adults ages 21-70 years were enrolled who were not taking a statin, had modestly elevated LDL-C, had ≥1 metabolic syndrome feature or type 2 diabetes, and were not taking anti-diabetic medication (N = 103). Water-only 24-hour fasting was performed twice-weekly for 4 weeks, then once-weekly for 22 weeks; controls ate ad libitum. The primary outcome was 26-week LDL-C change score. Secondary outcomes (requiring p ≤ 0.01) were 26-week changes in homeostatic model assessment of insulin resistance (HOMA-IR), Metabolic Syndrome Score (MSS), brain-derived neurotrophic factor (BDNF), and MicroCog general cognitive proficiency index (GCPi). Results Intermittent fasting (n = 50) and control (n = 53) subjects were, respectively, aged 49.3±12.0 and 47.0±9.8 years, predominantly female (66.0% & 67.9%), overweight (103±24 & 100±21 kg), and had modest LDL-C elevation (124±19 & 128±20 mg/dL). Drop-outs (n = 12 fasting, n = 20 control) provided an evaluable sample of n = 71 (n = 38 fasting, n = 33 control). Intermittent fasting did not change LDL-C (0.2±16.7 mg/dL) versus control (2.5±19.4 mg/dL; p = 0.59), but it improved HOMA-IR (-0.75±0.79 vs. -0.10±1.06; p = 0.004) and MSS (-0.34±4.72 vs. 0.31±1.98, p = 0.006). BDNF (p = 0.58), GCPi (p = 0.17), and weight (-1.7±4.7 kg vs. 0.2±3.5 kg, p = 0.06) were unchanged. Conclusions A low-frequency intermittent fasting regimen did not reduce LDL-C or improve cognitive function, but significantly reduced both HOMA-IR and MSS. Trial registration clinicaltrials.gov, NCT02770313

scholarly journals Effect of Epidemic Intermittent Fasting on Metabolic Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials

2021 ◽  
Author(s):  
Fan Yang ◽  
Can Liu ◽  
Xu Liu ◽  
Xiandu Pan ◽  
Xinye Li ◽  
...  
Keyword(s):  
Systematic Review ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Density Lipoprotein ◽  
Control Group ◽  
Intermittent Fasting ◽  
Controlled Trials ◽  
Randomized Controlled

Abstract Background and aims: Intermittent fasting (IF) has gained attention as a promising diet for weight loss and dysmetabolic diseases management. This systematic review aimed to investigate the effects of IF on metabolic syndrome (MetS). Methods: A systematic literature search was carried out using three electronic databases, namely PubMed, Embase, and the Cochrane Library, until October 2020. Randomized controlled trials that compared the IF intervention with a control group diet were included. Effect sizes were expressed as weighted mean difference (WMD) using a fixed-effects model and 95% confidence intervals (CI). Results: Forty-six studies were included. Compared to the ones within control groups, participants exposed to the IF intervention reduced their body weight (WMD, -1.78 kg; 95% CI, -2.21 to -1.35; p < 0.05), waist circumference (WMD, -1.19 cm; 95% CI, -1.8 to -0.57; p < 0.05), fat mass (WMD, -1.26 kg; 95% CI, -1.57 to -0.95; p < 0.05), body mass index (WMD, -0.58 kg/m2; 95% CI, -0.8 to -0.37; p < 0.05), systolic blood pressure (WMD, -2.14 mmHg; 95% CI: -3.54 to -0.73; p < 0.05), diastolic blood pressure (WMD: -1.38 mmHg, 95% CI, -2.35 to -0.41, p < 0.05), fasting blood glucose (WMD, -0.96 mg/dL; 95% CI, -1.89 to -0.03; p < 0.05), fasting insulin (WMD, -0.8 μU/mL; 95% CI, -1.15 to -0.44; p < 0.05), insulin resistance (WMD, -0.21; 95% CI, -0.36 to -0.05; p < 0.05), total cholesterol (WMD, -3.75 mg/dL; 95% CI, -6.64 to -0.85; p < 0.05), triglycerides (WMD, -7.54 mg/dL; 95% CI, -11.45 to -3.63; p < 0.05). No effects were observed for low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, or glycosylated hemoglobin. Conclusions: This meta-analysis supports IF’s role in the improvement of MetS, compared to a control group diet. Further research on IF interventions should take into account long-term and well-designed administration to draw definitive conclusions.

scholarly journals Additional benefit of yoga to standard lifestyle modification on blood pressure in prehypertensive subjects: a randomized controlled study

2014 ◽  
Vol 38 (1) ◽  
pp. 48-55 ◽  
Author(s):  
Ramkumar Thiyagarajan ◽  
Pravati Pal ◽  
Gopal Krushna Pal ◽  
Senthil Kumar Subramanian ◽  
Madanmohan Trakroo ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Lifestyle Modification ◽  
Additional Benefit ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Randomized Controlled

Effect of dietary sodium restriction on body water, blood pressure, and inflammation in hemodialysis patients: a prospective randomized controlled study

2013 ◽  
Vol 46 (1) ◽  
pp. 91-97 ◽  
Author(s):  
Lidiane Silva Rodrigues Telini ◽  
Gabriela de Carvalho Beduschi ◽  
Jacqueline Costa Teixeira Caramori ◽  
João Henrique Castro ◽  
Luis Cuadrado Martin ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Hemodialysis Patients ◽  
Body Water ◽  
Dietary Sodium ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Sodium Restriction ◽  
Randomized Controlled ◽  
Dietary Sodium Restriction

Self-help weight loss versus a structured commercial program after 26 weeks: a randomized controlled study

2000 ◽  
Vol 109 (4) ◽  
pp. 282-287 ◽  
Author(s):  
Stanley Heshka ◽  
Frank Greenway ◽  
James W Anderson ◽  
Richard L Atkinson ◽  
James O Hill ◽  
...  
Keyword(s):  
Weight Loss ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Randomized Controlled ◽  
Self Help ◽  
Commercial Program

scholarly journals Prospective Randomized Controlled Study to assess the Role of Dexmedetomidine on Perioperative Hemodynamics in Patients with Supratentorial Tumor undergoing Surgery

2017 ◽  
Vol 2 (1) ◽  
pp. 14-17
Author(s):  
Sachin Vaishnav ◽  
Anita Shetty ◽  
Manjula Sarkar
Keyword(s):  
Blood Pressure ◽  
Placebo Group ◽  
Arterial Blood Pressure ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Randomized Controlled ◽  
Arterial Blood ◽  
Supratentorial Tumor ◽  
Duration Of Surgery

ABSTRACT The stress response to an intense painful surgical stimulus is characterized by activation of the sympathetic nervous system and an increased secretion of the stress hormones. The ability of the alpha agonist dexmedetomidine (DEX) to decrease heart rate (HR) and arterial blood pressure in perioperative period was tested. One hundred and thirty two patients undergoing craniotomy for supratentorial tumor were randomly distributed to receive either saline (B group) or DEX (A group). The placebo group received saline, whereas the treatment group (A group) received a single bolus dose of DEX (1μg/kg) intravenously over 10 minutes before induction of anesthesia. Hemodynamic parameters, such as HR and arterial blood pressure were measured. Both the groups were comparable with respect to age, sex, American Society for Anesthesiologist grade, and duration of surgery. The arterial blood pressure and HR were found to be lower in the DEX group when compared with the placebo group. How to cite this article Vaishnav S, Shetty A, Sarkar M. Prospective Randomized Controlled Study to assess the Role of Dexmedetomidine on Perioperative Hemodynamics in Patients with Supratentorial Tumor undergoing Surgery. Res Inno in Anesth 2017;2(1):14-17.

Sign in / Sign up

Export Citation Format

Share Document